Get started
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

IONS chart


Full chart

IONS upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪5.33 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.44 USD
Net income (FY)
‪−366.29 M‬ USD
Revenue (FY)
‪787.65 M‬ USD
Shares float
‪145.54 M‬
Beta (1Y)
0.41

Employees


Employees (FY)
927
Change (1Y)
+131 +16.46%
Revenue / Employee (1Y)
‪849.67 K‬ USD
Net income / Employee (1Y)
‪−395.13 K‬ USD

About Ionis Pharmaceuticals, Inc.


Sector
Health Technology
CEO
Brett P. Monia
Headquarters
Carlsbad
Website
ionis.com
Founded
1989
FIGI
BBG000JH6683
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

IONS news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

IONS highest yielding bonds


IONS5104819
Ionis Pharmaceuticals, Inc. 0.125% 15-DEC-2024
Yield to maturity
9.79%
Maturity date
Dec 15, 2024
IONS5397611
Ionis Pharmaceuticals, Inc. 0.0% 01-APR-2026
Yield to maturity
2.56%
Maturity date
Apr 1, 2026
IONS5835891
Ionis Pharmaceuticals, Inc. 1.75% 15-JUN-2028
Yield to maturity
2.25%
Maturity date
Jun 15, 2028

Explore more bonds 

Frequently Asked Questions


The current price of IONS is 35.40 USD — it has increased by 4.89% in the past 24 hours. Watch Ionis Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Ionis Pharmaceuticals, Inc. stocks are traded under the ticker IONS.
IONS stock has fallen by −6.40% compared to the previous week, the month change is a −10.18% fall, over the last year Ionis Pharmaceuticals, Inc. has showed a −28.19% decrease.
We've gathered analysts' opinions on Ionis Pharmaceuticals, Inc. future price: according to them, IONS price has a max estimate of 77.00 USD and a min estimate of 37.00 USD. Watch IONS chart and read a more detailed Ionis Pharmaceuticals, Inc. stock forecast: see what analysts think of Ionis Pharmaceuticals, Inc. and suggest that you do with its stocks.
IONS reached its all-time high on Apr 8, 2019 with the price of 86.58 USD, and its all-time low was 2.50 USD and was reached on Mar 17, 2003. View more price dynamics on IONS chart.
See other stocks reaching their highest and lowest prices.
IONS stock is 6.17% volatile and has beta coefficient of 0.41. Track Ionis Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Ionis Pharmaceuticals, Inc. there?
Today Ionis Pharmaceuticals, Inc. has the market capitalization of ‪5.59 B‬, it has decreased by −10.67% over the last week.
Yes, you can track Ionis Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Ionis Pharmaceuticals, Inc. is going to release the next earnings report on Feb 19, 2025. Keep track of upcoming events with our Earnings Calendar.
IONS earnings for the last quarter are −0.95 USD per share, whereas the estimation was −1.13 USD resulting in a 15.61% surprise. The estimated earnings for the next quarter are −1.10 USD per share. See more details about Ionis Pharmaceuticals, Inc. earnings.
Ionis Pharmaceuticals, Inc. revenue for the last quarter amounts to ‪134.00 M‬ USD, despite the estimated figure of ‪129.57 M‬ USD. In the next quarter, revenue is expected to reach ‪141.30 M‬ USD.
IONS net income for the last quarter is ‪−140.48 M‬ USD, while the quarter before that showed ‪−66.27 M‬ USD of net income which accounts for −112.00% change. Track more Ionis Pharmaceuticals, Inc. financial stats to get the full picture.
No, IONS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 927.00 employees. See our rating of the largest employees — is Ionis Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Ionis Pharmaceuticals, Inc. EBITDA is ‪−347.93 M‬ USD, and current EBITDA margin is −42.05%. See more stats in Ionis Pharmaceuticals, Inc. financial statements.
Like other stocks, IONS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Ionis Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Ionis Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Ionis Pharmaceuticals, Inc. stock shows the sell signal. See more of Ionis Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.